{'fraction_non_alphanumeric': 0.06336550566512798, 'fraction_numerical': 0.09483843894250944, 'mean_word_length': 5.224543080939948, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 3, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MP63-09 IMPACT OF RAGE GENE POLYMORPHISMS ON UROTHELIAL CELL CARCINOMA CLINICOPATHOLOGIC CHARACTERISTICS AND LONG TERM SURVIVAL

INTRODUCTION AND OBJECTIVES: Urothelial cell carcinoma (UCC) is a common malignancy of urinary tract associated with gene effect and environmental factors. The receptor for advanced glycosylation endproducts (RAGE) is a transmembrane protein of the immunoglobulin superfamily which is well studied and specificity for multiple ligands that plays vital role in several pathophysiologic processes, including diabetes, Alzheimer disease, renal disease, cardiovascular disease, and cancer. The study aimed to explore the impact of RAGE gene polymorphisms on the clinicopathological status and survival of patients with UCC. METHODS: A total of 1,023 participants, including 431 patients with UCC and 592 healthy people as control group, were recruited for this study. Four polymorphisms of the RAGE gene—including -374T>A (rs1800624), -429T>C (rs1800625), 1704G>T (rs184003), Gly82Ser (rs2070600) were examed by a real-time PCR with the TaqMan assay. RESULTS: we found that individuals carrying at least one C allele at RAGE rs1800625 had a higher risk of developing UCC than those with wild-type allele (AOR=1.898, 95% CI=1.209-2.980). Additionally, participants carried this gene polymorphism associated with higher incidence of UCC in age≦65 (AOR=1.761, 95% CI=1.04-2.982), female (AOR=3.962, 95% CI=1.474-10.646) and without tobacco consumption (AOR=3.167, 95% CI=1.766-5.681). Subgroup analysis revealed in UCC patients under 65 years old, patients with rs1800625 variants have higher incidence of muscle invasive tumor (OR=1.274, 95% CI=1.025-1.582, p=0.029) and lymph node invasion (OR=1.833, 95% CI=1.145-2.935, p=0.012). TT polymorphism of rs184003 associated with worse disease specific survival (HR=7.574, 95% CI=2.519-22.768, p<0.001) and overall survival (HR=6.451, 95% CI=2.186-19.036, p<0.001) in UCC patients under 65 years old. CONCLUSIONS: This is the first reported correlation between RAGE polymorphisms and UCC risk. Individuals carry at least one C allele of rs1800625 of the RAGE associated with higher risk of UCC, especially in age≦65, female and without tobacco consumptom. TT polymorphism of rs184003 associated with worse disease specific survival and overall survival in age≦65. Table. No title available. Source of Funding: none